Ming Chiu Chan

Ming Chiu Chan

Auto-generated profile, based on publicly available information

Ming Chiu Chan

Princess Margaret Hospital, Hong KongHong Kong, Hong Kong

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
MCMing Chiu Chan
Ming Chiu Chan
YYYiu Cheong Yeung
Yiu Cheong Yeung
EYEllen Lok Man Yu
Ellen Lok Man Yu
WYWai Cho Yu
Wai Cho Yu
Purpose: Blood eosinophil is a readily available biomarker to reflect the eosinophilic inflammation in chronic obstructive pulmonary disease (COPD) patients, yet its association with exacerbation is inconclusive. It is uncertain which measurement, eosinophil percentage or absolute eosinophil count, should be used and what is the optimal cutoff for exacerbation prediction. Patients and Methods: A total of 247 COPD patients were included in this retrospective cohort study. Blood eosinophil during stable disease state, baseline demographics, and clinical characteristics in 12 months after the index complete blood count (CBC) were recorded. Exacerbation frequencies were compared between patients with high and low blood eosinophil percentage using 2% as cut-off. Logistic regression and receiver operating characteristics (ROC) curve analyses were conducted. Results: Patients with blood eosinophil ≥ 2% were associated with more frequent exacerbations than patients with eosinophil < 2% in the 12 months after the index CBC (mean exacerbation 1.07 vs 0.34, p < 0.001). Higher blood eosinophil percentage conferred a higher risk of exacerbation. Adjusted odds ratio for exacerbation in 12 months after the index CBC for blood eosinophil ≥ 2% was 2.98 (95% confidence interval = 1.42– 6.25). The area under the ROC curve of eosinophil percentage was significantly higher than that of absolute eosinophil count (0.678 vs 0.640, p = 0.010). The optimal cutoff of blood eosinophil percentage for exacerbation prediction was 2.8%. Conclusion: Blood eosinophilia was associated with higher exacerbation risk in COPD patients. Further studies are required to elucidate the mechanism of eosinophilic inflammation in COPD and determine the optimal treatment strategy to reduce exacerbations.

20 June 2006 in Transplantation Proceedings
Verified
Journal Article
Closed access
SLS.A. Lubitz
S.A. Lubitz
DBDavid A. A Baran
David A. A Baran
MAM.M. Alwarshetty
M.M. Alwarshetty
MZM.J. Zucker
M.J. Zucker
LAL.H. Arroyo
L.H. Arroyo
AGA.L. Gass
A.L. Gass

19 June 2024 in Respirology Case Reports
Verified
Journal Article
Open access
CLCheuk Cheung Derek Leung
Cheuk Cheung Derek Leung
HCHiu Ching Christy Chan
Hiu Ching Christy Chan
MCMing Chiu Chan
Ming Chiu Chan
YCYu Hong Chan
Yu Hong Chan
MHMan Ying Ho
Man Ying Ho
YYYiu Cheong Yeung
Yiu Cheong Yeung
Kikuchi‐Fujimoto Disease (KFD), also known as Kikuchi disease or Kikuchi histiocytic necrotizing lymphadenitis, is a rare and self‐limiting condition characterized by cervical lymphadenopathy and fever, primarily affecting young Asian adults. The aetiology of KFD remains unknown, although various infectious agents have been suggested as potential triggers. With the emergence of the COVID‐19 pandemic, cases of post‐COVID‐19 KFD and post‐COVID‐19 vaccine KFD have been reported. In this article, we present the first case of post‐COVID‐19 KFD in Hong Kong. A 24‐year‐old man developed fever and painful neck swelling 1 month after recovering from COVID‐19. Diagnostic evaluation, including ultrasound‐guided fine needle aspiration cytology (FNAC), confirmed the diagnosis of KFD. The patient's symptoms resolved spontaneously with supportive care. This case underscores the importance of considering KFD as a potential differential diagnosis in patients presenting with cervical lymphadenopathy and fever following COVID‐19 recovery or vaccination.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
MCMing Chiu Chan
Ming Chiu Chan
ALAntony K P Law
Antony K P Law
YYYiu Cheong Yeung
Yiu Cheong Yeung
Background: The role of type 2 biomarker fractional exhaled nitric oxide (FeNO) in COPD remains controversial. While inhaled corticosteroid (ICS) can suppress FeNO, no studies have targeted patients with persistently elevated FeNO on ICS. Aims: To investigate the clinical characteristics and exacerbation risk of COPD patients on ICS with high FeNO. Methods: A retrospective study was conducted in COPD patients on ICS who had FeNO test from January 2016 to December 2023 in Princess Margaret Hospital. Patients with previous physician-diagnosed asthma were excluded. The clinical characteristics of high (≥20ppb) and low FeNO (<20ppb) patients were compared by Chi-square and T-test. Association between COPD exacerbations in the past 12 months and FeNO was assessed by logistic regression. Results: 107 COPD patients on ICS performed FeNO test during the study period. 41 (38%) of them had high FeNO and 66 (62%) had low FeNO. High FeNO group had significantly higher blood eosinophil (470 cells/μL vs. 230 cells/μL, p = 0.028) and more exacerbations in previous 12 months (2.1 vs. 0.7, p = 0.007). On simple logistic regression, high FeNO and post-bronchodilator FEV1 had significant association with exacerbation, with OR 2.26 (p = 0.045) and 0.98 (p = 0.031) respectively. Adjusted OR for high FeNO was 2.48 (p = 0.037) on multiple logistic regression. Combining high FeNO and blood eosinophil further increased adjusted OR to 4.02 (p=0.022). Conclusion: COPD patients on ICS with elevated FeNO, especially with high blood eosinophil, had increased risk of exacerbations. Prospective study is required to further investigate the association.